Skip to content

Study · Randomized controlled trial · n = 24 · 1998

11 results

Treatment with the oral growth hormone secretagogue MK-677 increases markers of bone formation and bone resorption in obese young males.

Svensson J, Ohlsson C, Jansson JO, Murphy G, Wyss D, Krupa D, Cerchio K, Polvino W, Gertz B, Baylink D, Mohan S, Bengtsson BA

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research1 Jul 1998Cited by 23 (Europe PMC)

PMID9661080 (opens in a new tab)DOI10.1359/jbmr.1998.13.7.1158 (opens in a new tab)PepBankPUB-09661080
Source linkPubMedAsk about this study
Jump to 11 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

11 results from studies that gave the peptide. 11 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In obese males, MK‑677 increased the carboxy-terminal propeptide of type I procollagen compared with placebo.

    In plain wordsIn obese males, MK‑677 increased a type I procollagen formation marker compared with placebo.

    Peptide
    MK-677 (ibutamoren)
    Outcome
    IncreaseCarboxy-terminal propeptide of type I procollagen
    Study

    n = 24

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    25 mg/day · oral · 8 weeksAs given in this study (human).

    Measurements

    Carboxy-terminal propeptide of type I procollagen increase
    23%
    MK-677 vs placebo, with as little as 2 weeks of treatment
    P value for carboxy-terminal propeptide of type I procollagen increase
    < 0.01 unitless
    MK-677 vs. placebo, with as little as 2 weeks of treatment

    Source sentences

    Summary
    MK-677 increased markers of bone formation; a 23% increase in the carboxy-terminal propeptide of type I procollagen levels and a 28% increase in procollagen III peptide levels were seen with as little as 2 weeks of MK-677 treatment (p < 0.01 and p = 0.001 vs. placebo, respectively)
    2 context sentences
    Summary · context
    This was a randomized, double-blind, parallel, placebo-controlled study.
    Summary · context
    Twenty-four healthy obese males, 19-49 years of age, with body mass index > 30 kg/m2 were treated with MK-677 (25 mg/day; n = 12) or placebo (n = 12) for 8 weeks.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In obese males, MK‑677 increased procollagen III peptide compared with placebo.

    In plain wordsIn obese males, MK‑677 increased procollagen III peptide compared with placebo.

    Peptide
    MK-677 (ibutamoren)
    Outcome
    IncreaseProcollagen III peptide
    Study

    n = 24

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    25 mg/day · oral · 8 weeksAs given in this study (human).

    Measurements

    Procollagen III peptide increase
    28%
    MK-677 vs placebo, with as little as 2 weeks of treatment
    P value for procollagen III peptide increase
    0.001 unitless
    MK-677 vs. placebo, with as little as 2 weeks of treatment

    Source sentences

    Summary
    MK-677 increased markers of bone formation; a 23% increase in the carboxy-terminal propeptide of type I procollagen levels and a 28% increase in procollagen III peptide levels were seen with as little as 2 weeks of MK-677 treatment (p < 0.01 and p = 0.001 vs. placebo, respectively)
    2 context sentences
    Summary · context
    This was a randomized, double-blind, parallel, placebo-controlled study.
    Summary · context
    Twenty-four healthy obese males, 19-49 years of age, with body mass index > 30 kg/m2 were treated with MK-677 (25 mg/day; n = 12) or placebo (n = 12) for 8 weeks.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In obese males, MK‑677 increased osteocalcin at 8 weeks compared with placebo.

    In plain wordsIn obese males, MK‑677 increased osteocalcin at 8 weeks compared with placebo.

    Peptide
    MK-677 (ibutamoren)
    Outcome
    IncreaseOsteocalcin
    Study

    n = 24

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    25 mg/day · oral · 8 weeksAs given in this study (human).

    Measurements

    Osteocalcin increase
    15%
    MK-677 vs placebo, 8 weeks
    P value for serum osteocalcin increase
    < 0.01 unitless
    MK-677 vs. placebo, 8 weeks

    Source sentences

    Summary
    while a 15% increase in serum levels of osteocalcin was not detected until 8 weeks of treatment (p < 0.01 vs. placebo).
    2 context sentences
    Summary · context
    This was a randomized, double-blind, parallel, placebo-controlled study.
    Summary · context
    Twenty-four healthy obese males, 19-49 years of age, with body mass index > 30 kg/m2 were treated with MK-677 (25 mg/day; n = 12) or placebo (n = 12) for 8 weeks.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In obese males, MK‑677 increased serum type I collagen cross-linked telopeptide compared with placebo.

    In plain wordsIn obese males, MK‑677 increased a collagen breakdown marker compared with placebo.

    Peptide
    MK-677 (ibutamoren)
    Outcome
    IncreaseType I collagen cross-linked telopeptide
    Study

    n = 24

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    25 mg/day · oral · 8 weeksAs given in this study (human).

    Measurements

    Type I collagen cross-linked telopeptide increase
    26%
    MK-677 vs placebo, 8 weeks
    p value for Type I collagen cross-linked telopeptide
    0.001 p
    MK-677 vs placebo, 8 weeks

    Source sentences

    Summary
    Markers of bone resorption were induced within 2 weeks of treatment with MK-677; serum levels of the carboxy-terminal cross-linked telopeptide of type I collagen were increased 26% at 8 weeks (p = 0.001 vs. placebo)
    2 context sentences
    Summary · context
    This was a randomized, double-blind, parallel, placebo-controlled study.
    Summary · context
    Twenty-four healthy obese males, 19-49 years of age, with body mass index > 30 kg/m2 were treated with MK-677 (25 mg/day; n = 12) or placebo (n = 12) for 8 weeks.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In obese males, MK‑677 increased urine hydroxyproline/creatinine ratio compared with placebo.

    In plain wordsIn obese males, MK‑677 increased urine hydroxyproline/creatinine ratio compared with placebo.

    Peptide
    MK-677 (ibutamoren)
    Outcome
    IncreaseUrine hydroxyproline/creatinine ratio
    Study

    n = 24

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    25 mg/day · oral · 8 weeksAs given in this study (human).

    Measurements

    Urine hydroxyproline/creatinine ratio increase
    23%
    MK-677 vs placebo, 8 weeks
    p value for Urine hydroxyproline/creatinine ratio
    < 0.05 p
    MK-677 vs placebo, 8 weeks

    Source sentences

    Summary
    and urine hydroxyproline/creatinine and calcium/creatinine ratios at 8 weeks were increased by 23% (p < 0.05 vs. placebo) and 46% (p < 0.05 vs placebo), respectively,
    2 context sentences
    Summary · context
    This was a randomized, double-blind, parallel, placebo-controlled study.
    Summary · context
    Twenty-four healthy obese males, 19-49 years of age, with body mass index > 30 kg/m2 were treated with MK-677 (25 mg/day; n = 12) or placebo (n = 12) for 8 weeks.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In obese males, MK‑677 increased urine calcium/creatinine ratio compared with placebo.

    In plain wordsIn obese males, MK‑677 increased urine calcium/creatinine ratio compared with placebo.

    Peptide
    MK-677 (ibutamoren)
    Outcome
    IncreaseUrine calcium/creatinine ratio
    Study

    n = 24

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    25 mg/day · oral · 8 weeksAs given in this study (human).

    Measurements

    Urine calcium/creatinine ratio increase
    46%
    MK-677 vs placebo, 8 weeks
    p value for Urine calcium/creatinine ratio
    < 0.05 p
    MK-677 vs placebo, 8 weeks

    Source sentences

    Summary
    and urine hydroxyproline/creatinine and calcium/creatinine ratios at 8 weeks were increased by 23% (p < 0.05 vs. placebo) and 46% (p < 0.05 vs placebo), respectively,
    2 context sentences
    Summary · context
    This was a randomized, double-blind, parallel, placebo-controlled study.
    Summary · context
    Twenty-four healthy obese males, 19-49 years of age, with body mass index > 30 kg/m2 were treated with MK-677 (25 mg/day; n = 12) or placebo (n = 12) for 8 weeks.
  7. 07HumanRandomized controlled trialEfficacy outcome

    In obese males, MK‑677 increased IGFBP-5 compared with placebo.

    In plain wordsIn obese males, MK‑677 increased IGFBP-5 compared with placebo.

    Peptide
    MK-677 (ibutamoren)
    Outcome
    IncreaseIGFBP-5
    Study

    n = 24

    Comparator
    Placebo
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    25 mg/day · oral · 8 weeksAs given in this study (human).

    Measurements

    IGFBP-5 increase
    43 to 44%
    MK-677 vs placebo, 2-8 weeks
    p value for IGFBP-5
    < 0.01 p
    MK-677 vs placebo, 2-8 weeks

    Source sentences

    Summary
    MK-677 increased serum insulin-like growth factor binding protein-5 (IGFBP-5) by 43-44% after 2-8 weeks of treatment (p < 0.01 vs. placebo).
    2 context sentences
    Summary · context
    This was a randomized, double-blind, parallel, placebo-controlled study.
    Summary · context
    Twenty-four healthy obese males, 19-49 years of age, with body mass index > 30 kg/m2 were treated with MK-677 (25 mg/day; n = 12) or placebo (n = 12) for 8 weeks.
  8. 08HumanRandomized controlled trialEfficacy outcome

    In obese males, MK‑677 increased IGFBP-4 at 2 weeks compared with placebo.

    In plain wordsIn obese males, MK‑677 increased IGFBP-4 at 2 weeks compared with placebo.

    Peptide
    MK-677 (ibutamoren)
    Outcome
    IncreaseIGFBP-4 at 2 weeks
    Study

    n = 24

    Comparator
    Placebo
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    25 mg/day · oral · 2 weeksAs given in this study (human).

    Measurements

    IGFBP-4 increase
    25%
    MK-677 vs placebo, 2 weeks
    p value for IGFBP-4 at 2 weeks
    < 0.001 p
    MK-677 vs placebo, 2 weeks

    Source sentences

    Summary
    Serum IGFBP-4 was increased by 25% after 2 weeks of treatment (p < 0.001 vs. placebo) but no significant change from baseline was observed after 8 weeks of treatment.
    2 context sentences
    Summary · context
    This was a randomized, double-blind, parallel, placebo-controlled study.
    Summary · context
    Twenty-four healthy obese males, 19-49 years of age, with body mass index > 30 kg/m2 were treated with MK-677 (25 mg/day; n = 12) or placebo (n = 12) for 8 weeks.
  9. 09HumanRandomized controlled trialEfficacy outcome

    In obese males, MK‑677 did not significantly change plasma interleukin-6.

    In plain wordsIn obese males, MK‑677 did not significantly change plasma interleukin-6.

    Peptide
    MK-677 (ibutamoren)
    Outcome
    No significant changeInterleukin-6
    Study

    n = 24

    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    25 mg/day · oral · 8 weeksAs given in this study (human).

    Source sentences

    Summary
    Plasma interleukin-6 was not significantly changed by active treatment.
    2 context sentences
    Summary · context
    This was a randomized, double-blind, parallel, placebo-controlled study.
    Summary · context
    Twenty-four healthy obese males, 19-49 years of age, with body mass index > 30 kg/m2 were treated with MK-677 (25 mg/day; n = 12) or placebo (n = 12) for 8 weeks.
  10. 10HumanRandomized controlled trialEfficacy outcome

    In obese males, IGFBP-4 did not change significantly from baseline after 8 weeks of MK‑677.

    In plain wordsIn obese males, IGFBP-4 did not change significantly from baseline after 8 weeks of MK‑677.

    Peptide
    MK-677 (ibutamoren)
    Outcome
    No significant changeIGFBP-4 at 8 weeks
    Study

    n = 12

    Comparator
    Baseline
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    25 mg/day · oral · 8 weeksAs given in this study (human).

    Source sentences

    Summary
    Serum IGFBP-4 was increased by 25% after 2 weeks of treatment (p < 0.001 vs. placebo) but no significant change from baseline was observed after 8 weeks of treatment.
    2 context sentences
    Summary · context
    This was a randomized, double-blind, parallel, placebo-controlled study.
    Summary · context
    Twenty-four healthy obese males, 19-49 years of age, with body mass index > 30 kg/m2 were treated with MK-677 (25 mg/day; n = 12) or placebo (n = 12) for 8 weeks.
  11. 11HumanRandomized controlled trialEfficacy outcome

    In obese male volunteers, MK‑677 treatment produced a large increase in serum IGF-1.

    In plain wordsIn obese male volunteers, serum IGF-1 increased during MK‑677 treatment.

    Peptide
    MK-677 (ibutamoren)
    Outcome
    IncreaseSerum IGF-1
    Study

    n = 12

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    25 mg/day · oral · 8 weeksAs given in this study (human).

    Source sentences

    Summary
    Large increases in serum levels of IGF-1 and IGFBP-5 and a transient increase in serum IGFBP-4 were found.
    2 context sentences
    Summary · context
    This was a randomized, double-blind, parallel, placebo-controlled study.
    Summary · context
    Twenty-four healthy obese males, 19-49 years of age, with body mass index > 30 kg/m2 were treated with MK-677 (25 mg/day; n = 12) or placebo (n = 12) for 8 weeks.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.